1234616-26-2 Usage
Uses
Used in Pharmaceutical Industry:
BAY 12-9566 is used as a therapeutic agent for the treatment of conditions such as obesity, diabetes, and metabolic syndrome. Its ability to inhibit 11β-HSD1 and reduce cortisol levels in the body has shown promising results in preclinical studies, making it a potential drug candidate for these and other related disorders.
Used in Preclinical Research:
BAY 12-9566 is used as a research tool in preclinical studies to investigate the role of 11β-HSD1 in various physiological and pathological processes. Its potent and selective inhibition of the enzyme allows researchers to better understand the underlying mechanisms of cortisol regulation and its impact on health and disease.
Used in Drug Development:
BAY 12-9566 is being explored as a potential drug candidate for the development of new therapeutic agents targeting 11β-HSD1. Its promising results in preclinical studies have encouraged further research and development efforts to optimize its pharmacological properties and evaluate its safety and efficacy in clinical trials.
Check Digit Verification of cas no
The CAS Registry Mumber 1234616-26-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,4,6,1 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1234616-26:
(9*1)+(8*2)+(7*3)+(6*4)+(5*6)+(4*1)+(3*6)+(2*2)+(1*6)=132
132 % 10 = 2
So 1234616-26-2 is a valid CAS Registry Number.
1234616-26-2Relevant academic research and scientific papers
MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN
-
Paragraph 00252, (2020/09/08)
Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.
SERINE/THREONINE PAK1 INHIBITORS
-
, (2013/03/26)
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS
-
, (2013/07/05)
Compounds having the formula I wherein A, Rla, Rlb, R2, R3, R4, R5, R6, R7, Rs, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders
